Dostarlimab is given by a healthcare provider through an intravenous (IV) infusion. It is not something that can be self-administered at home. The process typically follows these steps:

1. Preparation: Your doctor or healthcare team will prepare the drug and set up the IV line for the infusion. Before starting the treatment, they will assess your overall health to ensure you are ready for the therapy.
2. IV Infusion: The medication is administered via IV over a period of time, usually about 30 to 60 minutes. You will be monitored during and after the infusion for any immediate side effects.
3. Post-Infusion Care: After receiving the infusion, you will be observed for a while to make sure there are no immediate reactions, especially during the first few infusions. Follow-up appointments will be scheduled to assess the effectiveness of the treatment.

You should follow all instructions provided by your healthcare provider regarding pre-treatment and post-treatment care, as well as any lifestyle adjustments that may help during therapy.

Dostarlimab works by targeting a protein known as PD-1 (programmed cell death protein 1), which is found on the surface of immune cells, specifically T-cells. Under normal conditions, PD-1 plays a role in keeping the immune system from attacking the body’s own cells by binding to other proteins like PD-L1. However, cancer cells can exploit this pathway by producing PD-L1, which binds to PD-1 on T-cells and prevents the immune system from recognizing and destroying cancer cells.

By inhibiting the PD-1 receptor, Dostarlimab blocks this “brake” on the immune system, essentially reviving the immune response so that T-cells can more effectively recognize and kill cancer cells. This mechanism is particularly useful in cancers that have developed the ability to evade the immune system.

Like other immunotherapies, Dostarlimab can cause side effects, though not everyone experiences them. Common side effects include:

• Fatigue: Feeling unusually tired is a common side effect of immunotherapy.
• Rashes: Skin rashes or itching may occur as a result of the immune system being stimulated.
• Diarrhea: Some patients experience gastrointestinal symptoms like diarrhea or nausea.
• Fever or Chills: Fever may occur as the body responds to the treatment.
• Cough or Shortness of Breath: Respiratory symptoms, including coughing and difficulty breathing, can occur during treatment.

While these side effects are typically manageable, serious immune-related side effects can occur due to the way Dostarlimab affects the immune system. These may include:

• Inflammation of Organs: Dostarlimab can cause inflammation in organs such as the lungs (pneumonitis), liver (hepatitis), colon (colitis), or thyroid (thyroiditis), which can lead to more severe complications if left untreated.
• Endocrine Problems: Some patients may develop problems with their hormone-producing glands, including the adrenal glands, thyroid, or pancreas, which can cause symptoms like weight changes, fatigue, or changes in blood sugar.

If you experience any severe side effects, such as difficulty breathing, chest pain, or swelling, it is important to seek medical attention immediately.

Before starting Dostarlimab, it’s important to discuss the following with your healthcare provider:

• Existing Autoimmune Conditions: If you have a history of autoimmune diseases, such as rheumatoid arthritis, lupus, or Crohn’s disease, immunotherapy may trigger flare-ups or cause new autoimmune symptoms.
  
  
• Infections: Since Dostarlimab works by stimulating the immune system, it can increase the risk of infections. Be sure to inform your doctor if you have a history of infections, particularly chronic or recurring infections.
  
  
• Organ Function: Dostarlimab can affect various organs, including the liver and kidneys. Your doctor will monitor your organ function throughout the treatment process to avoid serious complications.
  
  

Pregnancy and Breastfeeding: Dostarlimab is not recommended during pregnancy due to potential harm to the fetus. It’s essential to inform your doctor if you are pregnant or planning to become pregnant. Additionally, since the medication may pass into breast milk, breastfeeding is usually not advised during treatment.

Dostarlimab, as an immunotherapy, can interact with other medications or treatments, so it’s important to inform your healthcare provider about any other medications, including over-the-counter drugs, supplements, and herbal remedies you are taking. Some potential interactions include:

• Immunosuppressive Drugs: Combining Dostarlimab with other medications that suppress the immune system (such as corticosteroids or certain chemotherapy drugs) may reduce the effectiveness of the treatment.
  
  
• Other Cancer Treatments: If you are undergoing combination therapy (such as chemotherapy or targeted therapy), your doctor will closely monitor the treatment plan to ensure that the drugs work well together without increasing risks of side effects.
  
  
• Vaccines: Some vaccines, particularly live vaccines, may not be safe while receiving Dostarlimab, as it affects immune function. Be sure to discuss any vaccinations with your healthcare provider before starting treatment.
  

The typical dosage of Dostarlimab is administered intravenously (IV), and it is given by a healthcare provider in a hospital or outpatient setting. The specific dose and treatment schedule depend on the type of cancer being treated, the patient’s weight, and the overall treatment plan.

• Standard Dosing Schedule: For many cancers, Dostarlimab is given as an IV infusion every 3 weeks for the first few months, followed by less frequent infusions (such as every 6 weeks) if the patient is responding well to treatment.
  
  
• Infusion Duration: The infusion typically takes about 30 minutes to 1 hour depending on the treatment regimen and individual patient tolerance.
  
  
• Missed Dose: If you miss a dose, your doctor will reschedule the next infusion. It is important not to adjust the dosage on your own.
  

Before starting Dostarlimab, it’s important to discuss the following with your healthcare provider:

• Existing Autoimmune Conditions: If you have a history of autoimmune diseases, such as rheumatoid arthritis, lupus, or Crohn’s disease, immunotherapy may trigger flare-ups or cause new autoimmune symptoms.
  
  
• Infections: Since Dostarlimab works by stimulating the immune system, it can increase the risk of infections. Be sure to inform your doctor if you have a history of infections, particularly chronic or recurring infections.
  
  
• Organ Function: Dostarlimab can affect various organs, including the liver and kidneys. Your doctor will monitor your organ function throughout the treatment process to avoid serious complications.
  
  
• Pregnancy and Breastfeeding: Dostarlimab is not recommended during pregnancy due to potential harm to the fetus. It’s essential to inform your doctor if you are pregnant or planning to become pregnant. Additionally, since the medication may pass into breast milk, breastfeeding is usually not advised during treatment.
  

1 — What is dostarlimab?

• Dostarlimab is a humanized monoclonal antibody that targets the programmed death‑1 (PD‑1) receptor to enhance anti‑tumor immune responses.

 2 — What is dostarlimab used to treat?

• It is used to treat certain advanced or recurrent cancers; approvals include mismatch repair–deficient (dMMR)/microsatellite instability‑high (MSI‑H) solid tumors and specific endometrial cancers (check current labeling for indications).

 3 — How does dostarlimab work?

• It binds PD‑1 on T cells, blocking interaction with PD‑L1/PD‑L2 and restoring T‑cell–mediated immune attack on tumor cells.

 4 — How is dostarlimab administered?

• Given by intravenous (IV) infusion in a clinic or hospital setting according to the dosing schedule specified by the prescriber and product labeling.

 5 — What is the typical dosing schedule?

• Dosing varies by indication and treatment phase; refer to current prescribing information for induction and maintenance dosing schedules (commonly periodic IV infusions every few weeks).

 6 — Who should receive dostarlimab?

• Patients with tumors that meet the approved indications (e.g., dMMR/MSI‑H tumors or specified endometrial cancer patients) as determined by oncologists and appropriate testing.

 7 — Can dostarlimab be used with other cancer therapies?

• Yes—dostarlimab may be used alone or in combination with other agents depending on clinical trial data and approved regimens; combination use should follow evidence and treating oncologist judgment.

 8 — What are common side effects of dostarlimab?

• Common adverse effects include fatigue, nausea, diarrhea, constipation, pyrexia, decreased appetite, and infusion‑related reactions.

 9 — What are serious risks associated with dostarlimab?

• Immune‑related adverse events (irAEs) can be serious and affect multiple organs (pneumonitis, colitis, hepatitis, endocrinopathies like hypothyroidism/thyroiditis, adrenal insufficiency, nephritis, severe skin reactions). Prompt recognition and management are crucial.

 10 — How are immune‑related adverse events managed?

• Mild irAEs may be managed with corticosteroids and symptomatic care; moderate to severe events often require treatment interruption and high‑dose corticosteroids or other immunosuppression per guidelines and product labeling.

 11 — Can dostarlimab cause infusion reactions?

• Yes—infusion‑related reactions can occur. Infusion rates may be modified, and premedication considered per institutional protocol.

 12 — Is testing required before starting dostarlimab?

• Tumor biomarker testing (e.g., dMMR/MSI status) is often required or recommended to identify patients likely to benefit for certain indications; review current indication requirements.

 13 — Can patients with autoimmune disease receive dostarlimab?

• Patients with active, severe autoimmune disease were often excluded from trials and may have higher risks of exacerbation; use requires careful risk‑benefit assessment and specialist input.

 14 — Can dostarlimab be used during pregnancy or breastfeeding?

• Immune checkpoint inhibitors may cause fetal harm; pregnancy should be avoided during treatment and for a period after. Breastfeeding is generally not recommended during therapy — discuss risks with the oncology team.

 15 — How long does it take to see a response?

• Some patients respond within weeks to months; timing varies by tumor type and individual. Durable responses can occur but are not guaranteed.

 16 — How is treatment response monitored?

• Through clinical assessment, imaging (CT/MRI/PET), tumor markers when applicable, and monitoring for adverse events at regular visits.

 17 — Are there drug interactions with dostarlimab?

• Dostarlimab has no known direct pharmacokinetic drug interactions typical of small molecules, but concomitant immunosuppressive therapies (like high‑dose corticosteroids) can reduce efficacy of immune checkpoint inhibitors.

 18 — Can dostarlimab be given to elderly patients?

• Age alone is not a contraindication; clinical status, comorbidities, and potential risks should guide therapy. Trials included older adults and dosing is generally the same.

19 — What should patients report while on dostarlimab?

• Report new or worsening symptoms — e.g., cough, shortness of breath, severe diarrhea, abdominal pain, jaundice, severe fatigue, mood or vision changes, severe skin rash, or signs of hormonal dysfunction.

20 — How long is dostarlimab continued?

• Duration depends on indication, response, toxicity, and clinical judgment. Some protocols continue until disease progression or unacceptable toxicity; check specific treatment guidelines.